AMACR Monoclonal Antibody

說明書

中文名稱：

AMACR鼠單克隆抗體
貨號：

CSB-MA546610
規格：

￥1320
圖片：
IHC image of CSB-MA546610 diluted at 1:100 and staining in paraffin-embedded human prostate cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-mouse IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CUSABIO貨號：CSB-MA546610 AMACR單克隆抗體是針對人類α-甲基酰基輔酶A消旋酶（AMACR）研發的高特異性科研試劑，該靶標作為脂肪酸β氧化代謝途徑中的關鍵酶，在前列腺癌、肝細胞癌等腫瘤組織的異常高表達使其成為重要的腫瘤生物標志物。本產品采用雜交瘤技術制備，經嚴格驗證適用于酶聯免疫吸附實驗（ELISA）和免疫組化（IHC）兩大技術平臺，在0.1-1000ng/mL線性范圍內展現優異檢測性能，其抗原識別表位位于AMACR蛋白特異性結構域，確保檢測結果的準確性和可重復性。在腫瘤分子機制研究中，該抗體可有效用于前列腺癌、結直腸癌及腎細胞癌等惡性腫瘤的分子分型研究，通過組織切片中AMACR蛋白的定位分析揭示腫瘤代謝特征，同時支持體外培養細胞的蛋白表達水平檢測。作為經過多實驗體系驗證的AMACR抗體，其在癌癥代謝組學、腫瘤微環境研究及抗腫瘤藥物開發等領域具有重要科研價值，為探索AMACR介導的脂代謝異常與腫瘤發生發展的分子關聯提供可靠工具。
產品名稱：

Mouse anti-Homo sapiens (Human) AMACR Monoclonal antibody
Uniprot No.：

Q9UHK6
基因名：

AMACR
別名：

2 arylpropionyl CoA epimerase antibody; 2 methylacyl CoA racemase antibody; 2-methylacyl-CoA racemase antibody; Alpha methylacyl CoA racemase antibody; Alpha methylacyl Coenzyme A racemase antibody; Alpha methylacyl-CoA racemase deficiency; included antibody; Alpha-methylacyl-CoA racemase antibody; Amacr antibody; AMACR deficiency; included antibody; AMACR_HUMAN antibody; CBAS4 antibody; Da1-8 antibody; EC 5.1.99.4 antibody; Macr1 antibody; Methylacyl CoA racemase alpha antibody; RACE antibody; RM antibody
宿主：

Mouse
反應種屬：

Human
免疫原：

Synthesized peptide derived from human AMACR
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

IgG1, Kappa
純化方式：

The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
克隆號：

17F8
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Catalyzes the interconversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters. Acts only on coenzyme A thioesters, not on free fatty acids, and accepts as substrates a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis), and arylpropionic acids like the anti-inflammatory drug ibuprofen (2-(4-isobutylphenyl)propionic acid) but neither 3-methyl-branched nor linear-chain acyl-CoAs.
基因功能參考文獻：
1. High expression of AMACR was not only a key adverse prognostic factor but also a potential therapeutic target in oral squamous cell carcinoma PMID: 29725255
2. AMACR expression was studied in normal mucosa of the colon, adenomas with different degrees of dysplasia, colonic carcinomas, lymph nodes and liver metastases of colonic carcinomas. Expression was nearly absent in samples of normal mucosa, increased in both adenomas and carcinomas, decreased in lymph node metastases but was significantly increased in liver metastases. PMID: 29179959
3. IMP3 has a similar specificity, but a better sensitivity, intensity, and extent of reactivity in comparison with AMACR, and may be used as an alternative to AMACR, in support of the diagnosis of BE-dysplasia and EAC PMID: 26766126
4. As an adjunct to biopsy, AMACR and HMWCK have value for resolving diagnostically challenging cases PMID: 28508828
5. Single nucleotide polymorphism in AMACR gene is associated with schizophrenia risk loci with potential implications for neurocognitive performance. PMID: 28902459
6. Results show that AMACR expression is significantly high in patients with prostate cancer. PMID: 29277318
7. High AMACR expression is associated with prostate cancer. PMID: 28741117
8. AMACR staining was positively expressed in 86 of the prostate carcinoma cases and completely absent in remaining 12. PMID: 28384107
9. Data show a significant association between Alpha-methylacyl-CoA racemase (AMACR) and ERG protein with prognostic implication in prostate cancer. PMID: 27271990
10. AMACR is expressed in most of the chordomas but only in a minority of chondrosarcomas. AMACR may serve as IHC marker of chordoma with differentiating ability comparable to that of beta-catenin. PMID: 26888362
11. AMACR transcripts were detected in all radical prostatectomy(RP)-prostate cancer and RP-Benign samples but not in non-cancerous cystoprostatectomy samples, which suggest a global increase of AMACR expression in cancerous prostates. PMID: 26928323
12. AMACRwas not regulated in the white blood cells of multiple sclerosis patients PMID: 26648339
13. study showed that 34betaE12 is the most appropriate negative marker to combine with alpha-methylacyl coenzyme A racemase as a positive marker for the diagnosis of prostate adenocarcinoma[34betaE12] PMID: 20189848
14. The D175G and M9V polymorphisms of the AMACR gene are related to prostate cancer. The S201L polymorphism might be linked with prostate cancer risk. no association was observed between K277E or Q239H polymorphisms and susceptibility to prostate cancer. PMID: 25773837
15. AMACR amplification is a mechanism driving increased mRNA and protein expression and conferring aggressiveness through heightened cell proliferation in gastrointestinal stromal tumors PMID: 25473890
16. In diagnosis of ovarian clear cell carcinoma, AMACR is highly specific but suboptimally sensitive. PMID: 25551297
17. Overexpressed AMACR in myxofibrosarcomas can be amplification-driven, associated with tumor aggressiveness, and may be relevant as a druggable target. PMID: 25384383
18. Combination of p63 and AMACR is of great additional value in combating the morphologically suspicious cases and should be used on case to case basis especially in prostatic needle biopsies and small foci lesions. PMID: 25313761
19. Our results suggest AMACR as an immunohistochemical marker for distinguishing malignant melanomas and dysplastic nevi from conventional melanocytic nevi. PMID: 25149154
20. AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of hepatocellular carcinoma after hepatectomy. PMID: 25092674
21. The overexpression of AMACR in prostate cancer was not associated with dietary influences on phytanic acid. PMID: 25307752
22. AMACR overexpression was identified as an important prognosticator and a potential therapeutic target in the future PMID: 24833092
23. AMACR is a useful immunohistochemical marker for the differential diagnosis of solid pseudopapillary neoplasms of the pancreas. PMID: 24675392
24. AMACR should be the first-line positive marker for confirmation of a diagnosis of minimal adenocarcinoma of the prostate. PMID: 24705308
25. Genetic variations of AMACR are associated with the risk of sporadic prostate cancer that underwent radical prostatectomy in Koreans. PMID: 24383053
26. Strong AMACR expression is associated with an increased risk of neoplastic progression in Barrett's esophagus. PMID: 24004067
27. in the subgroup of papillary renal cell carcinoma both a higher grade and a presence of distant metastases were associated with a lower percentage of alpha-methylacyl CoA racemase (AMACR)expressing tumors. PMID: 22009118
28. role of AMACR in drug metabolism, cancer and drug design PMID: 23376124
29. Case Report: AMACR homozygous mutation responsible for adult onset alpha-methyl-acyl-CoA racemase deficiency. PMID: 20821052
30. These findings indicate that AMACR expression is strongly associated with endometrial clear cell carcionma and displays a relatively robust diagnostic test performance. PMID: 24119561
31. Overall disease-free survival tended to be worse in AMACR-positive patients, and in adenocarcinoma subgroup, it was significantly shorter PMID: 23235347
32. ERG immunohistochemistry could be considered in a second round of immunostaining of select difficult cases of foamy gland carcinoma of the prostate with low AMACR expression. PMID: 23797726
33. Of the cases of clear cell renal carcinoma there was immunoreactivity for alpha-methylacyl-CoA racemase and strong diffuse immuno-positivity for cytokeratin. PMID: 23434146
34. Alpha methylacyl-COA racemase cannot discriminate hepatocellular carcinoma from liver cell dysplasiA, although it can separate both of them from nondysplastic lesions. PMID: 22542076
35. The sensitivity and specificity of AMACR for the diagnosis of prostate adenocarcinoma and benign glands in Japanese patients are lower than those previously reported in Western countries. PMID: 22593005
36. Our results indicate that alpha-methylacyl-coenzyme A racemase is a useful marker for distinguishing between grade 1 and grade 2 neuroendocrine tumours, and neuroendocrine carcinoma of the stomach PMID: 22782380
37. High AMACR is associated with prostate cancer. PMID: 22248277
38. Alpha-methylacyl-coenzyme A racemase expression is associated with mucin phenotypes of gastric neoplasia, particularly with the expression of CDX2 and MUC5AC. PMID: 22078291
39. AMACR can be considered a more accurate marker than PTOV1 in the identification of high-grade prostatic intraepithelial neoplasia (HGPIN) and of prostate cancer. PMID: 22507319
40. Our study showed that 34betaE12 is the most appropriate negative marker to combine with AMACR as a positive marker for the diagnosis of prostate adenocarcinoma. PMID: 20189848
41. This report shows the first high-throughput screen for the discovery of novel AMACR inhibitors, characterizes the first nonsubstrate-based inhibitors, and validates that AMACR is a viable chemotherapeutic target in vitro. PMID: 21441411
42. Overexpression of alpha-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas PMID: 21457159
43. A combination of high molecular weight cytokeratin and alpha-methylacyl CoA racemase is of great value in combating the morphologically suspicious cases and significantly increasing the diagnostic accuracy in prostate cancer. PMID: 21176184
44. The results suggest that AMACR may play a significant role in susceptibility to schizophrenia in male patients. PMID: 20875727
45. Our data suggest that AMACR variants have better power than total AMACR in discriminating between CaP and adjacent normal tissue. These findings may be useful for the development of future diagnostic assays PMID: 21195844
46. Examine P504S expressing circulating prostate cells as a marker for prostate cancer. PMID: 20664974
47. AMACR shows promise as a marker to indicate indefinite dysplasia in Barrett's oesophagus. PMID: 20636793
48. Results describe alpha-methylacyl CoA racemase (AMACR) expression in relation to various dysplasia phenotypes and clinicopathological parameters of sporadic colorectal adenomas. PMID: 20503447
49. marker of differential diagnosis of kidney cancer PMID: 20102405
50. The expression of AMACR is increased in benign sebaceous glands and sebaceous hyperplasia; with decreasing AMACR expression in tumors with less sebaceous differentiation PMID: 19638170
顯示更多

收起更多
相關疾病：

Alpha-methylacyl-CoA racemase deficiency (AMACRD); Congenital bile acid synthesis defect 4 (CBAS4)
亞細胞定位：

Peroxisome. Mitochondrion.
蛋白家族：

CaiB/BaiF CoA-transferase family
數據庫鏈接：

HGNC: 451

OMIM: 214950

KEGG: hsa:23600

STRING: 9606.ENSP00000371517

UniGene: Hs.508343

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human